ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6000-Perth-Royal-Perth-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
10
trial(s) found.
NCT07710885
Advanced
Phase 3
Recruiting
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (
FOENIX-BTC
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
antimetabolite
pan-FGFR inhibitor,irreversible
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT07651618
Advanced
Phase 2
Not yet recruiting
PERTIL-01
: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
Aldesleukin
Cyclophosphamide
Fludarabine
IL-2 variant
alkylating agent
antimetabolite
cancer therapy
cancer therapy,IL-2-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,IL-2-targeting
Melanoma
Skin cancer
WA
6000 - Perth - Royal Perth Hospital
NCT05866458
Curative
Recruiting
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy (
ROSALIE
)
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2487 - Cudgen - Tweed Valley Hospital
VIC
3002 - East Melbourne - Victoria Breast & Oncology Care
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3165 - Bentleigh East - Monash Medical Centre - Moorabbin
3844 - Traralgon - Latrobe Regional Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
ACTRN12625001031459
Haem
Phase 2
Not yet recruiting
Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.
Cyclophosphamide
Fludarabine
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Multiple myeloma
WA
6000 - Perth - Royal Perth Hospital
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 43 in
/home/topowadl/articanz.org/table.php
on line
440
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M--(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
Cyclophosphamide
Fludarabine
Radiotherapy
alkylating agent
antimetabolite
cancer therapy
cytotoxic chemotherapy
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
ACTRN12607000589482
Advanced
Phase 3
Recruiting
Phase III randomised study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux 'Registered trade mark') versus placebo in combination with Cetuximab (Erbitux 'Registered trade mark') in patients with K-Ras wild type tumours previously treated with combination chemotherapy for metastatic colorectal carcinoma to compare overall survival. (
CO.20
)
anti-EGFR monoclonal antibody
placebo
Colorectal cancer
NSW
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare
QLD
4999 - Unspecified - Clinical Trial Site QLD
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (6)
Not yet recruiting (4)
Recruitment Country and State
WA (10)
NSW (7)
QLD (7)
VIC (6)
SA (5)
ACT (2)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (4)
Phase 3 (2)
Trial Type
Haem (5)
Advanced (3)
Curative (1)
Paed (1)
Cancer Therapy Class
DNA methyltransferase
30%
Bcl2
20%
FGFR
10%
FGFR1
10%
FGFR1/2/3
10%
FGFR2
10%
FGFR3
10%
FGFR4
10%
PD-1
10%
PD-1/PD-L1
10%
PD-L1
10%
IL-2
10%
KMT2A
10%
GM-CSF
10%
EGFR
10%
Facility
6000 - Perth - Royal Perth Hospital (10)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
3168 - Clayton - Monash Medical Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
NA
2031 - Randwick - Prince of Wales Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
2605 - Garran - The Canberra Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
3066 - Epping - Northern Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2060 - North Sydney - Mater Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
3002 - East Melbourne - Victoria Breast & Oncology Care (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
3165 - Bentleigh East - Monash Medical Centre - Moorabbin (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare (1)
4999 - Unspecified - Clinical Trial Site QLD (1)
Cancer Type
Cancer
Haematological malignancy
Solid tumour
Leukaemia
Gastrointestinal cancer
Acute myeloid leukaemia
Myeloid leukaemia
Biliary tract cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Melanoma
Skin cancer
Breast cancer
Multiple myeloma
Plasma cell disorder
Chronic myelomonocytic leukaemia
Myelodysplastic/Myeloproliferative disease
Myeloproliferative neoplasm
Acute lymphoblastic leukaemia
B-cell malignancy
Chronic lymphocytic leukaemia
Lymphoid leukaemia
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy